BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30126426)

  • 1. NPM1 alternative transcripts are upregulated in acute myeloid and lymphoblastic leukemia and their expression level affects patient outcome.
    Handschuh L; Wojciechowski P; Kazmierczak M; Marcinkowska-Swojak M; Luczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    J Transl Med; 2018 Aug; 16(1):232. PubMed ID: 30126426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
    Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
    Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA expression profile in cytogenetically normal acute myeloid leukemia identifies a distinct signature and a new biomarker in NPM1-mutated patients.
    De Clara E; Gourvest M; Ma H; Vergez F; Tosolini M; Dejean S; Demur C; Delabesse E; Recher C; Touriol C; Martelli MP; Falini B; Brousset P; Bousquet M
    Haematologica; 2017 Oct; 102(10):1718-1726. PubMed ID: 28679652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
    Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
    Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NPM1 gene mutation in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Sofan MA; Elmasry S; Salem DA; Bazid MM
    Clin Lab; 2014; 60(11):1813-22. PubMed ID: 25648021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Minimal Residual Disease in Standard-Risk AML.
    Ivey A; Hills RK; Simpson MA; Jovanovic JV; Gilkes A; Grech A; Patel Y; Bhudia N; Farah H; Mason J; Wall K; Akiki S; Griffiths M; Solomon E; McCaughan F; Linch DC; Gale RE; Vyas P; Freeman SD; Russell N; Burnett AK; Grimwade D;
    N Engl J Med; 2016 Feb; 374(5):422-33. PubMed ID: 26789727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival.
    Kapelko-Słowik K; Urbaniak-Kujda D; Wołowiec D; Jaźwiec B; Dybko J; Jakubaszko J; Słowik M; Kuliczkowski K
    Postepy Hig Med Dosw (Online); 2013 Jun; 67():553-9. PubMed ID: 23752607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia.
    Konoplev S; Lin P; Yin CC; Lin E; Nogueras González GM; Kantarjian HM; Andreeff M; Medeiros LJ; Konopleva M
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):686-92. PubMed ID: 24035716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular profiling of adult acute myeloid and lymphoid leukemia in a major referral center in Lebanon: a 10-year experience report and review of the literature.
    Assaf N; El-Cheikh J; Bazarbachi A; Salem Z; Farra C; Chakhachiro Z; Nassif S; Zaatari G; Mahfouz R
    Mol Biol Rep; 2019 Apr; 46(2):2003-2011. PubMed ID: 30701458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of CD4 is correlated with an unfavorable prognosis in wild-type NPM1, FLT3-ITD-negative cytogenetically normal adult acute myeloid leukemia.
    Guo RJ; Atenafu EG; Schimmer AD; Minden MD; Chang H
    Int J Lab Hematol; 2017 Aug; 39(4):429-437. PubMed ID: 28318150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of lymphoid enhancer-binding factor 1 expression in acute myeloid leukemia.
    Fu Y; Zhu H; Wu W; Xu J; Chen T; Xu B; Qian S; Li J; Liu P
    Leuk Lymphoma; 2014 Feb; 55(2):371-7. PubMed ID: 23713453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.
    Ovcharenko D; Stölzel F; Poitz D; Fierro F; Schaich M; Neubauer A; Kelnar K; Davison T; Müller-Tidow C; Thiede C; Bornhäuser M; Ehninger G; Brown D; Illmer T
    Exp Hematol; 2011 Oct; 39(10):1030-1042.e7. PubMed ID: 21784052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
    Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
    J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. INPP4B promotes cell survival via SGK3 activation in NPM1-mutated leukemia.
    Jin H; Yang L; Wang L; Yang Z; Zhan Q; Tao Y; Zou Q; Tang Y; Xian J; Zhang S; Jing Y; Zhang L
    J Exp Clin Cancer Res; 2018 Jan; 37(1):8. PubMed ID: 29343273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease detection in acute myeloid leukemia by mutant nucleophosmin (NPM1): comparison with WT1 gene expression.
    Barragan E; Pajuelo JC; Ballester S; Fuster O; Cervera J; Moscardo F; Senent L; Such E; Sanz MA; Bolufer P
    Clin Chim Acta; 2008 Sep; 395(1-2):120-3. PubMed ID: 18590714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilineage dysplasia as assessed by immunophenotype has no impact on clinical-biological features and outcome of NPM1-mutated acute myeloid leukemia.
    Mannelli F; Ponziani V; Bonetti MI; Bencini S; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Rondelli T; Benelli M; Caporale R; Grazia Gelli AM; Peruzzi B; Longo G; Bosi A
    Exp Hematol; 2015 Oct; 43(10):869-879.e22. PubMed ID: 26101160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoplasmic expression of nucleophosmin accurately predicts mutation in the nucleophosmin gene in patients with acute myeloid leukemia and normal karyotype.
    Luo J; Qi C; Xu W; Kamel-Reid S; Brandwein J; Chang H
    Am J Clin Pathol; 2010 Jan; 133(1):34-40. PubMed ID: 20023256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification.
    Marcinkowska-Swojak M; Handschuh L; Wojciechowski P; Goralski M; Tomaszewski K; Kazmierczak M; Lewandowski K; Komarnicki M; Blazewicz J; Figlerowicz M; Kozlowski P
    Mutat Res; 2016 Apr; 786():14-26. PubMed ID: 26894557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.